Drug-resistant infections are hard to treat precisely because the usual antibiotics have stopped working, so new classes of antimicrobials draw attention even at the earliest stage. On 7 October 2026, Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) reported what it called positive new Bisphosphocin preclinical data in urinary tract and pulmonary infection models. The results are laboratory and animal findings, not human data, and they come from a company announcement rather than a peer-reviewed paper.
What the company reported
- Urinary tract infection model: Nu-8, given directly into the bladder as a 10% solution, reduced E. coli growth by up to 97% in infected rodents. A vehicle control showed no comparable effect.
- Pulmonary models: aerosol formulations showed activity against infections caused by Acinetobacter species, Pseudomonas aeruginosa and Aspergillus fumigatus.
- Laboratory testing: the compounds were active against resistant bacteria linked to urinary tract and pulmonary infections and against organisms that form biofilms.
- Next step: further development work to select a lead candidate for early clinical testing.
What are Bisphosphocins?
Bisphosphocins are a class of antimicrobials that the company says kills bacteria by destabilising their cell membranes, in a manner that depends on pH and concentration. The company reports that this typically happens in under a minute of exposure in laboratory tests. Because the mechanism is physical rather than targeting a single bacterial enzyme, the company argues that resistance is less likely to develop quickly. That is the company’s interpretation and has not been established in patients.
The lead candidate, Nu-3, is being developed as a topical treatment for infected diabetic foot ulcers. The newly reported work concerns other compounds in the class, aimed at harder-to-reach sites: the bladder and the lungs.
Reading the 97% figure carefully
“Up to 97%” is a best-case number from a rodent model, in which the drug was placed directly into the bladder as a concentrated solution. Three cautions apply. First, animal infection models differ from human disease, and the dose and route used may not translate to patients. Second, “up to” describes the most favourable result rather than the average. Third, the company did not, in the material we reviewed, publish group sizes, variability or statistical tests.
In our assessment, the data are best viewed as a signal worth following rather than evidence of clinical benefit. Many compounds that perform well in rodent infection models do not reach the clinic, and the step from animal data to a safe, effective human dose is where most antimicrobial candidates fall away.
Why urinary and lung infections?
Complicated urinary tract infections and hospital-acquired lung infections are among the settings where resistant bacteria cause the most trouble. Pseudomonas aeruginosa and Acinetobacter are well-known hospital pathogens that resist many standard antibiotics, and Aspergillus fumigatus is a mould that can cause serious lung disease in vulnerable patients. Biofilms, communities of bacteria that cling to surfaces such as catheters, add to the difficulty because they shield microbes from drugs.
Public-health bodies including the World Health Organization and the U.S. Centers for Disease Control and Prevention treat antimicrobial resistance as a major and growing threat. In a May 2026 announcement about its lead programme, the company cited estimates that resistance directly causes about 1.27 million deaths a year and contributes to nearly 5 million, a figure it attributed to global burden estimates.
The earlier resistance data
The October update follows a May 2026 release on Nu-3. In that work, bacteria were repeatedly exposed to Nu-3 over 21 days. The company reported that the minimum inhibitory concentration of Nu-3 rose only slightly for E. coli and did not change for MRSA, while a ciprofloxacin control rose more than 2,000-fold for E. coli and more than 600-fold for MRSA. Nu-3 also kept its potency against bacteria that had become resistant to ciprofloxacin, which the company interprets as no cross-resistance.
Those are laboratory results and the “no cross-resistance” conclusion is the company’s own reading. Still, they explain why investors and clinicians are watching the class: if the findings hold, resistance may be slower to emerge than with conventional antibiotics.
The clinical programme that matters most
The only human data for this class will come from Nu-3, the topical gel in an ongoing Phase 2a trial in mildly infected diabetic foot ulcers. The company says topline results are expected in the first quarter of 2027. The registered design can be checked on ClinicalTrials.gov. Until those results arrive, claims about the class in people remain unproven.
What we do not know
- Study details: animal numbers, dosing and statistics were not available in the material we reviewed.
- Safety: the reporting we reviewed does not describe toxicology for Nu-8 or the aerosol formulations.
- Lead candidate: the company has not yet chosen which compound will go into early clinical testing for these indications.
- Funding and timelines: no timeline was given for starting trials in urinary or pulmonary infection.
What to watch next
- The Nu-3 Phase 2a topline readout expected in Q1 2027.
- Selection of a lead Bisphosphocin candidate for urinary or pulmonary infection.
- Peer-reviewed publication of the preclinical data.
- Any additional resistance or safety studies.
For related early-stage drug development coverage, read our report on Beactica’s BEA-28 preclinical candidate for solid tumours, and browse more pharmaceutical news.
Frequently asked questions
What did Lakewood-Amedex report?
Positive preclinical data for Bisphosphocin compounds in urinary tract and pulmonary infection models, including up to a 97% reduction in E. coli growth in infected rodents with Nu-8.
Are Bisphosphocins in human trials?
The lead candidate Nu-3 is in a Phase 2a trial for mildly infected diabetic foot ulcers. The compounds in the new urinary and pulmonary work are preclinical.
What bacteria were tested?
E. coli in the urinary model, and Acinetobacter, Pseudomonas aeruginosa and Aspergillus fumigatus in pulmonary models.
When are the next results due?
The company expects Nu-3 Phase 2a topline results in the first quarter of 2027.
Does this mean a new antibiotic is coming?
Not yet. Preclinical results are an early step, and most candidates do not reach approval.
How we reported this: we used the company’s announcements of 7 October 2026 and 1 May 2026. All data are company-reported, preclinical and not independently verified. Last updated: 8 October 2026. This article is news reporting, not medical or investment advice.
